Drugs that target the epidermal growth factor receptor, or EGFR, have been used for a number of cancers. But these drugs called EGFR inhibitors, such as cetuximab, have not been very effective against colon cancer.
The new study, however, shows that drugs that target the closely related receptor ERBB3 would probably be much more effective than EGFR inhibitors at treating most colorectal cancers, said David Threadgill, Ph.D., adjunct professor in the department of genetics at UNC and lead author of the study. He also is a member of the UNC Lineberger Comprehensive Cancer Center and a professor in the genetics department at North Carolina State University.
The study is published online August 17 in the Journal of Clinical Investigation.
The researchers genetically blocked ERBB3 in a mouse model of colon cancer and in human colon cancer cell lines. “If you genetically remove ERBB3, as you would if you were pharmacologically targeting it, then the mice rarely develop colon cancer,” Threadgill said.
In the human colon cancer cell lines that are resistant to EGFR inhibitors, cell death increased dramatically when ERBB3 was genetically removed. “So ERBB3 is essential for preventing colon cancer cells from dying,” Threadgill said. Now Threadgill is testing a pharmacologic inhibitor to get the same anti-ERBB3 effect they achieved with genetics. “If we can use an inhibitor to block ERBB3, then it should be a very potent anti-cancer therapeutic,” he said.
More broadly, the study suggests a new path for developing anti-cancer drugs.
Many cancer therapeutics, such as EGFR inhibitors, target proteins that are kinases—enzymes that initiate a cascade of signals that tell cells to reproduce. But ERBB3 is a pseudo-kinase; it functions only by binding with other proteins that have kinase activity.
“This study shows that targets that historically hadn’t been considered because they don’t have the typical activities of a kinase can be equally if not more important in supporting cancer cells,” Threadgill said.
Other UNC co-authors are Ming Yu, a former graduate student in the department of genetics and the Program in Oral Biology; Christina Pannicia, former undergraduate student in biology; and Daekee Lee, formerly of the genetics department and now of Ewha Womans University in Seoul, Republic of Korea. Other co-authors are Eunjung Lee, Hyunok Kim and Kyoungmi Kim of Ewha Womans University; and Jonathan M. Kurie and Yanan Yang of the University of Texas M.D. Anderson Cancer Center.
The study was funded by the National Cancer Institute, the National Science Foundation, and the Korea Science and Engineering Foundation.
Les Lang | EurekAlert!
What happens in the cell nucleus after fertilization
06.12.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Materials Sciences
06.12.2016 | Medical Engineering
06.12.2016 | Power and Electrical Engineering